

Krebs Biochemicals & Industries Limited

CIN : L24110AP1991PLC103912



10th August, 2017

To,
The Manager,
Department of Corporate Relations,
BSE Limited,
P J Towers, Dalal Street,
Fort, Mumbai- 400001.

To,
The Manager,
Listing Department,
National Stock Exchange of India Ltd.,
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai- 400051.

Dear Sir/Madam,

Sub: Outcome of Board Meeting held on 10th August, 2017.

We refer to the above mentioned subject, we herewith intimate the Exchange that the Board of Directors at their meeting held on 10th August 2017 has considered and approved interalia the following:

- a) Unaudited Financial results and Limited Review Report for the quarter ended 30th June, 2017 which are enclosed herewith.
- b) Notice of the 25th Annual General Meeting, which is scheduled to be held on Tuesday, 26th September 2017 at 10:00 AM, along with the Directors Report and annexures thereto.

Kindly note that the meeting commenced at 11:00 AM and concluded at 02:25 PM

This is for the information and records of the Exchange, Please.

Thanking You,
Yours Faithfully,

For Krebs Biochemicals & Industries Limited


Haritha Varanasi
Company Secretary



Encl as above

KREBS BIOCHEMICALS & INDUSTRIES LIMITED

CIN:L24110AP1991PLC103912

Registered Office: Kothapalli Village, Kasimkota Mandal, Ankapalli, Visakhapatnam, Andhra Pradesh - 531 031

Corporate Office: 8-2-577/B, Plot No:34, 3rd Floor, Maas Heights, Road No:8, Banjara Hills, Hyderabad - 500 034

STANDALONE FINANCIAL RESULTS FOR THE QUARTER / PERIOD ENDED 30TH JUNE 2017

(Rs. In lacs)

		Quarter Ended			For The
		30.06.2017	31.03.2017	30.06.2016	Year Ending
		(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
	PART - 1				
1	Income from Operations				
	a) Net Sales / Income from Operations	76.38	188.43	7.14	197.02
	b) Other Operating Income	39.00	39.00	39.00	156.00
2	Other Income	4.03	0.94	1.13	7.52
3	Total Income (1+2)	119.41	228.37	47.26	360.54
4	Expenses				
	a Cost of Material Consumed	30.41	133.16	0.11	133.99
	b Changes in inventories of finished goods, work-in-progress	54.08	(40.84)	4.07	(41.68)
	c Employee benefits expense	149.04	147.41	123.93	562.59
	d Depreciation and Amortisation expense	101.86	111.10	104.09	423.37
	e. Other Manufacturing Expenses	172.96	(51.13)	71.29	176.80
	f. Other Expenses	77.27	114.86	56.60	321.32
	Total Expenses	585.61	414.57	360.10	1,576.39
5	Profit / (Loss) from ordinary activities before finance costs & exceptional items (3 ± 4)	(466.20)	(186.19)	(312.84)	(1,215.85)
6	Finance Costs	108.19	141.13	50.67	348.85
7	Profit / (Loss) from Ordinary Activities after Finance Costs but before exceptional items (5 ± 6)	(574.39)	(327.32)	(363.51)	(1,564.70)
8	Exceptional Itmes:				
	a) Depletion in Value of Inventory	(22.52)	(53.27)	(8.37)	(67.56)
	b) Amounts Written Back	-	25.92	-	31.66
	c) Prior Period Income/(Expenditure)	3.56	(10.80)	-	(4.34)
9	Profit / (Loss) from ordinary activities before Tax (7 ± 8)	(593.36)	(365.48)	(371.88)	(1,604.94)
10	Tax Expense	-	-	-	-
	a) Current Tax	-	-	-	-
	b) Deferred Tax	-	-	-	-
11	Net Profit / (Loss) for the period (9 ± 10)	(593.36)	(365.48)	(371.88)	(1,604.94)
12	Other Comprehensive Income	(21.20)	451.26	-	451.26
13	Total Comprehensive Income after Tax(11 ± 12)	(614.56)	85.79	(371.88)	(1,153.68)
14	Paid-up Equity Share Capital (Face Value Rs. 10/- each)	-	-	-	-
15	Reserve Excluding Revaluation Reserves as per Balance Sheet of previous Accounting Year	-	-	-	-
16	Earning Per Share (before extraordinary Items)				
(i)	(of Rs.10/- each) (not Annualised)				
	(a) Basic	(4.47)	0.62	(2.71)	(8.39)
	(b) Diluted	(4.47)	0.62	(2.79)	(8.46)
(ii)	Earning Per Share (after extraordinary Items) (of Rs.10/- each) (not Annualised)				
	(a) Basic	(4.47)	0.62	(2.71)	(8.39)
	(b) Diluted	(4.47)	0.62	(2.79)	(8.46)
	<i>See accompanying notes to the Financial results</i>				

- The above results have been reviewed by the Audit Committee at its meeting held on 10th August, 2017, and approved by the Board of Directors of the Company at its meeting held on 10th August, 2017. The results are subject to limited review by statutory auditors.
- The Company is operating in one segment only hence no segment results have been disclosed.
- Figures have been regrouped, rearranged wherever necessary.
- The above financial results are prepared in accordance with IND AS notified under the Company (Indian Accounting Standards) Rules, 2015.
- The results for the quarter ended 31.03.2017 are the balancing figures between the audited figures in respect of the full financial year and published year to date figures upto third quarter of the relevant financial year.

Place : Hyderabad
Date : 10.08.2017



AVINASH RAVI
Managing Director
DIN: 01616152



PAVULURI & Co.

CHARTERED ACCOUNTANTS

105, 1st Block, 1st Floor, Divya Shakti Complex,
Ameerpet, Hyderabad - 500 016.
Ph : 040 - 2373 1837, 4025 8691
Fax : 040 - 2374 8729
Email : pavuluriandco@gmail.com
pavuluriandco@hotmail.com

Limited Review Report

**Review Report to
The Board of Directors,
KREBS BIO-CHEMICALS & INDUSTRIES LIMITED**

We have reviewed the accompanying statement of unaudited financial results of **M/s. KREBS BIO-CHEMICALS & INDUSTRIES LIMITED** ("the company") for the quarter ended **30th June, 2017** pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, read with circular No CIR/CFD/CMD/15/2015 dated 30th November 2015 and CIR/CFD/FAC/62/2016 dated 5th July 2016.

The preparation of the statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim financial reporting (Ind AS 34) specified under section 133 of the Companies Act 2013 read with Rule 3 of Companies (Indian Accounting Standards) Rules, 2015 and SEBI circular No CIR/CFD/CMD/15/2015 dated 30th November 2015 and CIR/CFD/FAC/62/2016 dated 5th July 2016 is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, *Review of Interim Financial Information performed by the independent Auditor of Entity* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above nothing has come to our attention that causes us to believe that the accompanying statement of un-audited financial results for the Quarter ended **30th June, 2017** prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim financial reporting (Ind AS 34) specified under section 133 of the Companies Act 2013 read with relevant rules issued thereafter and other recognized accounting practices and policies has disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, read with circular No CIR/CFD/CMD/15/2015 dated 30th November 2015 and CIR/CFD/FAC/62/2016 dated 5th July 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For PAVULURI & Co.
Chartered Accountants
Firm Regn. No: 012194S

N. Rajesh
(CA. N. RAJESH)
PARTNER
M.No: 223169



Place: Hyderabad
Date: 10.08.2017